Pain Therapeutics is a biopharmaceutical company that develops novel drugs. Its drugs target severe chronic pain, such as pain associated with osteoarthritis, lower back pain or irritable bowel syndrome. Pain Therapeutics has three drug candidates in clinical development, which includes Oxytrex, Remoxy and PTI-901. The company s two most advanced drugs, Oxytrex and PTI-901, are in Phase III clinical trials. The company believes the target market for its three drug candidates exceeds $3 billion per year. Pain Therapeutics experience represents a cross-section of drug development disciplines, which includes preclinical development, clinical development, medical affairs, regulatory, pharmaceutical development and supply chain management. Pain Therapeutics is headquartered in San Mateo, Calif.